News

Physicians need to help others. It's within them, a creed to which they'vesworn. In cities reeling from the worst terrorist attacks in U.S. history,frustrated dermatologists wanted to help but couldn't.

Q. I have lots of dark pink spots on my feet from last summer'sblisters. Is there a way to banish them before sandal season?

Better, more consistent public access to databases now available per request of taxpayers

Upholding medical ethics during an era of advertising, managed care, and in-office dispensing requires stringent self-review of practice procedures

While complication rates for chemical peels that havebeen described in the literature are low enough so that the risk:benefitratios are good

Opponent of restrictions in place around country says rules might result in more deaths, not fewer

Doctors should ask their patients about any herbal remedies they may be taking before undergoing surgery since they may cause complications during the operation

Recombinant human keratinocyte growth factor provide patients mouth and throat pain relief

Small study shows potential of mouthwash therapy

Regimen of cisplatin, vinblastine, temozolomide, IL-2, and INFa-2b shows to be active and well tolerated

Fourteen of 3,304 lovastatin recipients developed melanoma during five years of follow-up, compared to 27 of 3,301 placebo patients

Doses of interferon alfa-2b used in the treatment of melanoma may cause retinopathy,

Applied Genetics Inc. Dermatics is continuing to study its Dimericine lotion for skin cancer prevention in at-risk patients.

Bioglam Pharma Inc. launched ADOXA Tablets, the first and only doxycycline monohydrate tablets for the treatment of severe acne.

Systemic, topical corticosteroid-induced adverse effects may be mitigatedby barrier repair therapy

Psychologist recommends treatment with selective serotonin reuptakeinhibitors rather than topicals

The FDA approved a supplemental new drug application on valacyclovir (Valtrex), allowing a shorter course of treatment

Use of the antidepressant bupropion (Wellbutrin) appearsto be associated with the development of erythema multiforme,

Understanding of biochemical pathways could form foundation of new class of gene-based agents

An investigational topical drug that bindsat a specific RNA target and inhibits its expression

Inflammatory diseases such as psoriasis, HPV-associated lesions, andskin infections may benefit from PDT

Dermatologists see benefit of periodic patient surveys but expressconcern over link to bonus payments from insurance companies

In the wake of its settling a lawsuit regardingthe setting aside of initial election results for the position of president-elect2001, the American Academy of Dermatology's board of directors is takingsteps

Brugge, Belgium - Recalcitrant cases of onychomycosis can usually be treated successfully by following an individualized approach to further management that is based on confirmation of the diagnosis and investigation of contributing causes for prior treatment failure, Christa de Cuyper, M.D., said.

NEW YORK - OrCel, an engineered tissue produced by Ortec International, showed greater than 100 percent improvement over standard of care in diabetic ulcers the size of 6 cm2 or less,according to interim 12-week clinical data from a trial pilot conducted by the company.

Two-in-one product simplifies shaving, moisturizes skin

NEW ORLEANS - Treating verrucae with pulsed dye lasers may be improved with longer wavelengths by reducing the need for repeat treatments, Jenifer Lloyd, D.O., reported at the American Society for Laser Medicine and Surgery meeting.

NEW ORLEANS - Laser hair removal around the eyes or on other parts of the face - increasingly popular procedures the last two years -should be carried out cautiously, Randal Tanh Pham, M.D., F.A.C.S., said at the American Society of Laser Medicine and Surgery meeting.

NEW ORLEANS - A new yellow light laser successfully destroys Class I red telangiectasias in the legs of most patients, according to Neil S. Sadick, M.D.

WASHINGTON - Imiquimod 5 percent cream (Aldara) continues to demonstrate promise as an effective and well tolerated topical therapy for the treatment of primary, superficial basal cell carcinoma, according to results from foreign and domestic Phase II dose-response studies presented at the annual meeting of the American Academy of Dermatology.